MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ccd.70376

Медицинская библиотека · Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025

Transcatheter Aortic Valve-in-Valve Implantation for Failing Stentless Bioprosthetic Aortic Valves: An International Multicentre Retrospective Analysis.

Rayner Clare, Paleri Sarang, Satpal Arri, Tomii Daijiro, Pilgrim Thomas, Codner Pablo, Kornowski Ran, Mangieri Antonio, Tartaglia Francesco, Mauri Victor, De Backer Ole, Kobari Yusuke, Nombela-Franco Luis, Ielasi Alfonso, Akodad Mariama, Sava Ruxandra, Patterson Tiffany, Redwood Simon, Adams Heath

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Valve-in-valve aortic valve implantation (ViV-TAVI) offers a less invasive treatment option for patients with a failing surgical bioprosthesis, avoiding the need for redo surgery. ViV-TAVI within a stentless bioprosthetic valve poses unique technical challenges. We report an international, multicentre experience evaluating procedural and clinical outcomes for patients undergoing ViV-TAVI for failed stentless bioprosthetic aortic valves.

AIMS: To evaluate the procedural feasibility, safety, and clinical outcomes of ViV-TAVI performed for failed stentless bioprosthetic aortic valves in an international, multicentre cohort.

METHODS

We retrospectively analysed 65 patients who underwent ViV-TAVI for stentless valve failure between 2010 and 2024. Outcome endpoints were based on the Valve Academic Research Consortium 3 (VARC-3) criteria.

RESULTS

Sixty-five patients (mean age 78.8 ± 10.2 years; 66.1% male; mean STS-PROM 6.9 ± 4.7) were included. The mean interval between surgical valve implantation and failure was 12.9 ± 4.1 years, with regurgitation the predominant mechanism of valve dysfunction (52.3%). Procedural success was achieved in 92.3%. 17 patients (26.2%) had upfront coronary protection. Despite this, six patients required unplanned percutaneous coronary intervention (PCI) for coronary obstruction. The 30-day and 1-year mortality rate was 0% and 8% respectively.

CONCLUSIONS

ViV-TAVI was an effective intervention for patients with failing stentless bioprosthetic valves, with high procedural success rates despite unique technical challenges. Careful preprocedural imaging, planning, and implementation of coronary protection strategies are critical for optimal patient outcomes.

Для цитирования: Rayner Clare, Paleri Sarang, Satpal Arri, Tomii Daijiro, Pilgrim Thomas, Codner Pablo, Kornowski Ran, Mangieri Antonio, Tartaglia Francesco, Mauri Victor, De Backer Ole, Kobari Yusuke, Nombela-Franco Luis, Ielasi Alfonso, Akodad Mariama, Sava Ruxandra, Patterson Tiffany, Redwood Simon, Adams Heath. Transcatheter Aortic Valve-in-Valve Implantation for Failing Stentless Bioprosthetic Aortic Valves: An International Multicentre Retrospective Analysis.. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2025. DOI: 10.1002/ccd.70376.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.